(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $19.52
发出时间: 15 Feb 2024 @ 03:28
回报率: -18.47%
上一信号: Feb 15 - 00:53
上一信号:
回报率: 2.55 %
Live Chart Being Loaded With Signals
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong...
Stats | |
---|---|
今日成交量 | 362 617 |
平均成交量 | 639 958 |
市值 | 1.57B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-0.930 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.55 |
ATR14 | $0.0180 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Smiley Joshua L | Buy | 7 145 | American Depositary Shares |
2024-04-04 | Smiley Joshua L | Sell | 1 988 | American Depositary Shares |
2024-04-03 | Smiley Joshua L | Sell | 7 145 | Restricted Share Units |
2024-04-03 | Reinhart Harald | Buy | 5 270 | American Depositary Shares |
2024-04-04 | Reinhart Harald | Sell | 2 105 | American Depositary Shares |
INSIDER POWER |
---|
72.37 |
Last 100 transactions |
Buy: 2 027 943 | Sell: 363 897 |
音量 相关性
Zai Lab Ltd 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Zai Lab Ltd 相关性 - 货币/商品
Zai Lab Ltd 财务报表
Annual | 2023 |
营收: | $266.72M |
毛利润: | $170.90M (64.08 %) |
EPS: | $-3.46 |
FY | 2023 |
营收: | $266.72M |
毛利润: | $170.90M (64.08 %) |
EPS: | $-3.46 |
FY | 2022 |
营收: | $215.04M |
毛利润: | $141.02M (65.58 %) |
EPS: | $-5.03 |
FY | 2021 |
营收: | $144.31M |
毛利润: | $92.07M (63.80 %) |
EPS: | $-9.07 |
Financial Reports:
No articles found.
Zai Lab Ltd
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。